Business Description
ResMed Inc
NAICS : 339112
SIC : 3841
ISIN : US7611521078
Total Employee Number:
10,600Compare
Compare
Traded in other countries / regions
RMD.USARMD.AustraliaRMEA.Germany0KW4.UK1RMD.ItalyRMD.AustriaRMD.MexicoR1MD34.Brazil IPO Date
2025-04-28Description
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.97 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 0.39 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 11.12 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.8 | |||||
3-Year EBITDA Growth Rate | 17.7 | |||||
3-Year EPS without NRI Growth Rate | 18.2 | |||||
3-Year FCF Growth Rate | 103.6 | |||||
3-Year Book Growth Rate | 21.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.96 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.04 | |||||
9-Day RSI | 82.58 | |||||
14-Day RSI | 77.06 | |||||
3-1 Month Momentum % | -19.49 | |||||
6-1 Month Momentum % | -24.7 | |||||
12-1 Month Momentum % | -28.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.01 | |||||
Quick Ratio | 2.33 | |||||
Cash Ratio | 1.23 | |||||
Days Inventory | 156.83 | |||||
Days Sales Outstanding | 62.47 | |||||
Days Payable | 44.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.09 | |||||
Dividend Payout Ratio | 0.22 | |||||
3-Year Dividend Growth Rate | 8.1 | |||||
Forward Dividend Yield % | 1.1 | |||||
5-Year Yield-on-Cost % | 1.56 | |||||
Shareholder Yield % | 2.79 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.59 | |||||
Operating Margin % | 34.6 | |||||
Net Margin % | 27.44 | |||||
EBITDA Margin % | 39.36 | |||||
FCF Margin % | 31.39 | |||||
OCF Margin % | 34.17 | |||||
ROE % | 24.95 | |||||
ROA % | 18.38 | |||||
ROIC % | 24.9 | |||||
3-Year ROIIC % | 31.69 | |||||
ROC (Joel Greenblatt) % | 94.86 | |||||
ROCE % | 26.97 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.06 | |||||
Forward PE Ratio | 17.92 | |||||
PE Ratio without NRI | 20.28 | |||||
Shiller PE Ratio | 37.56 | |||||
Price-to-Owner-Earnings | 19.08 | |||||
PEG Ratio | 1.48 | |||||
PS Ratio | 5.78 | |||||
PB Ratio | 4.88 | |||||
Price-to-Tangible-Book | 10.47 | |||||
Price-to-Free-Cash-Flow | 18.43 | |||||
Price-to-Operating-Cash-Flow | 16.93 | |||||
EV-to-EBIT | 16.11 | |||||
EV-to-Forward-EBIT | 14.85 | |||||
EV-to-EBITDA | 14.16 | |||||
EV-to-Forward-EBITDA | 13.61 | |||||
EV-to-Revenue | 5.57 | |||||
EV-to-Forward-Revenue | 5.07 | |||||
EV-to-FCF | 17.78 | |||||
Price-to-GF-Value | 0.8 | |||||
Price-to-Projected-FCF | 1.62 | |||||
Price-to-DCF (Earnings Based) | 0.96 | |||||
Price-to-DCF (FCF Based) | 1.03 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.32 | |||||
Price-to-Graham-Number | 3.07 | |||||
| Price-to-Net-Current-Asset-Value | 17.88 | |||||
Earnings Yield (Greenblatt) % | 6.21 | |||||
FCF Yield % | 5.48 | |||||
Forward Rate of Return (Yacktman) % | 18.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ResMed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4,759.87 | ||
| EPS (TTM) (€) | 8.915 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 16.99 | ||
| 14-Day RSI | 77.06 | ||
| 14-Day ATR (€) | 2.019966 | ||
| 20-Day SMA (€) | 167.9875 | ||
| 12-1 Month Momentum % | -28.23 | ||
| 52-Week Range (€) | 157.6 - 243.2 | ||
| Shares Outstanding (Mil) | 145.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ResMed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ResMed Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-19 15:00 | In 135 days | ||
| First quarter earnings conference call for 2027 | 2026-10-30 16:30 | In 115 days | ||
| First quarter earnings results for 2027 | 2026-10-30 | In 114 days | ||
| Annual report for 2026 | 2026-08-07 | In 30 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 30 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-06 | In 29 days | ||
| 46th Annual William Blair Growth Stock Conference | 2026-06-02 16:40 | 170.25 (+0.00%) | ||
| USD 0.600000 Cash Dividend | 2026-05-14 | 170.25 (+0.00%) | ||
| Third quarter earnings conference call for 2026 | 2026-04-30 16:30 | 189.65 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-04-30 | 189.65 (+0.00%) |
Show
Entries
ResMed Inc Frequently Asked Questions
What is ResMed Inc(MIL:1RMD)'s stock price today?
The current price of MIL:1RMD is €188.95. The 52 week high of MIL:1RMD is €243.20 and 52 week low is €157.60.
When is next earnings date of ResMed Inc(MIL:1RMD)?
The next earnings date of ResMed Inc(MIL:1RMD) is 2026-08-06.
Does ResMed Inc(MIL:1RMD) pay dividends? If so, how much?
The Dividend Yield %  of ResMed Inc(MIL:1RMD) is 1.09% (As of Today), Highest Dividend Payout Ratio of ResMed Inc(MIL:1RMD) was 0.47. The lowest was 0.22. And the median was 0.31. The  Forward Dividend Yield % of ResMed Inc(MIL:1RMD) is 1.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on ResMed Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers